Clicky

Arrowhead Research Corporation(ARWR) News

Date Title
May 9 Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results
May 2 Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma
Apr 29 Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences
Apr 26 Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars
Apr 24 Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results
Apr 24 Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease
Apr 16 Turnstone Biologics Appoints William Waddill to its Board of Directors
Apr 16 Institutional investors may adopt severe steps after Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) latest 6.6% drop adds to a year losses
Apr 7 Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo
Apr 4 Insider Sell: Chief Discovery/Trans Medicine James Hamilton Sells 6,000 Shares of Arrowhead ...
Mar 25 Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data
Mar 11 The 3 Most Undervalued Russell 2000 Stocks to Buy in March 2024
Mar 9 Arrowhead Pharmaceuticals Inc CFO Kenneth Myszkowski Sells 40,000 Shares
Mar 8 Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy
Mar 6 Is Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Expensive For A Reason? A Look At Its Intrinsic Value
Mar 4 Arrowhead Pharmaceuticals to Participate in Upcoming March 2024 Conferences
Feb 8 Arrowhead Pharmaceuticals First Quarter 2024 Earnings: Misses Expectations
Feb 8 ARWR: Pipeline Reprioritization to Reduce Cash Burn by up to $100 Million This Fiscal Year
Feb 7 Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q1 2024 Earnings Call Transcript
Feb 7 Q1 2024 Arrowhead Pharmaceuticals Inc Earnings Call